MX2009004179A - Uso de valerato de estradiol o 17?-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina. - Google Patents

Uso de valerato de estradiol o 17?-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina.

Info

Publication number
MX2009004179A
MX2009004179A MX2009004179A MX2009004179A MX2009004179A MX 2009004179 A MX2009004179 A MX 2009004179A MX 2009004179 A MX2009004179 A MX 2009004179A MX 2009004179 A MX2009004179 A MX 2009004179A MX 2009004179 A MX2009004179 A MX 2009004179A
Authority
MX
Mexico
Prior art keywords
estradiol
combination
dienogest
maintaining
increasing
Prior art date
Application number
MX2009004179A
Other languages
English (en)
Inventor
Holger Zimmermann
Susan Zeun
Susanne Parke
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2009004179A publication Critical patent/MX2009004179A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se relaciona con el uso de valerato de estradiol o 17?-estradiol (estradiol) en combinación con 17a-cianometil-17-?-h idroxiestra-4,9-dien-3-ona (dienogest) en un producto combinado de múltiples fases o de una sola fase en una terapia oral para mantener y/o incrementar la libido femenina, cuando fuera apropiado también junto con una contracepción oral. Las unidades de dosis diarias totales de la combinación de múltiples fases y del placebo farmacéuticamente aceptable o las unidades de dosis diarias de la combinación de una sola fase y sin ingrediente activo y sin placebo corresponden a 28 días.
MX2009004179A 2006-10-20 2007-10-12 Uso de valerato de estradiol o 17?-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina. MX2009004179A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06022091 2006-10-20
EP07009373A EP1930010A1 (de) 2006-10-20 2007-05-10 Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
PCT/EP2007/008866 WO2008046559A1 (de) 2006-10-20 2007-10-12 VERWENDUNG VON ESTRADIOLVALERAT ODER 17ß-ESTRADIOL IN KOMBINATION MIT DIENOGEST ZUR ORALEN THERAPIE FÜR DEN ERHALT UND/ODER STEIGERUNG DER WEIBLICHEN LIBIDO

Publications (1)

Publication Number Publication Date
MX2009004179A true MX2009004179A (es) 2009-04-30

Family

ID=38809728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004179A MX2009004179A (es) 2006-10-20 2007-10-12 Uso de valerato de estradiol o 17?-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina.

Country Status (17)

Country Link
US (1) US8349820B2 (es)
EP (2) EP1930010A1 (es)
JP (1) JP2010506867A (es)
KR (1) KR20090080989A (es)
AU (1) AU2007312626A1 (es)
BR (1) BRPI0717462A2 (es)
CA (1) CA2666829C (es)
CO (1) CO6160297A2 (es)
CR (1) CR10732A (es)
EA (1) EA016631B1 (es)
GT (1) GT200900090A (es)
IL (1) IL198200A (es)
MX (1) MX2009004179A (es)
NO (1) NO20091954L (es)
NZ (1) NZ576336A (es)
SV (1) SV2009003231A (es)
WO (1) WO2008046559A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US20070088011A1 (en) * 2005-10-17 2007-04-19 Susan Zeun Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4168068A (en) 1969-07-22 1971-01-28 Unisearch Limited Improvements in or relating to oral contraceptives
US3639600A (en) 1969-08-28 1972-02-01 Upjohn Co Process of establishing cyclicity in a human female
US3795734A (en) 1970-04-20 1974-03-05 American Home Prod Cyclic regimen of hormone administration for contraception
US4066757A (en) 1973-03-26 1978-01-03 Ortho Pharmaceutical Corporation Oral contraceptive regimen
DE2365103C3 (de) 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
DE2431704A1 (de) 1974-07-02 1976-01-22 Asche Ag Stufenkombinationspraeparate per kontrazeption
DE2645307A1 (de) 1976-10-05 1978-04-06 Schering Ag Neue mittel und neue methoden zur behandlung klimakterischer ausfallerscheinungen
NL8001593A (nl) 1980-03-18 1981-10-16 Akzo Nv Meerfasisch combinatiepreparaat voor orale anticonceptie.
US4390531A (en) 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
US4544554A (en) 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3341638A1 (de) 1983-11-17 1984-05-03 Hermann Dr.rer.nat. 8000 München Heßlinger Dreiphasen-praeparat zur empfaengnisverhuetung aus ethinyloestradiol und lynestrenol
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
AU581486B2 (en) 1985-12-30 1989-02-23 Warner-Lambert Company Graduated estrogen contraceptive
DK174724B1 (da) 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
CA2005933A1 (en) 1989-01-09 1990-07-09 Jesse Hipps, Sr. Photohardenable composition containing five member aromatic group with imine moiety
IE71203B1 (en) 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
DE4104385C1 (es) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4308406C1 (de) 1993-03-12 1994-06-16 Jenapharm Gmbh Kombinationspräparat zur Kontrazeption
DE4313926A1 (de) 1993-04-28 1994-11-03 Jenapharm Gmbh Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption
DE4339934C2 (de) 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Ovulationshemmendes Mittel zur hormonalen Kontrazeption
NL9301562A (nl) 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19525017A1 (de) 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19540253C2 (de) 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
KR100518102B1 (ko) 1996-07-26 2005-10-04 와이어쓰 프로게스틴과 에스트로겐의 혼합물을 포함하는 단일상 피임약 키트
US5858405A (en) 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
WO1998004246A2 (en) 1996-07-26 1998-02-05 American Home Prod Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
AU4043597A (en) 1996-07-26 1998-02-20 American Home Products Corporation Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen
SI0917466T1 (en) 1996-07-26 2005-02-28 Wyeth Oral contraceptive
US6987101B1 (en) 1996-12-20 2006-01-17 Schering Aktiengesellschaft Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
DE19654609A1 (de) 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19908762A1 (de) 1999-02-18 2000-08-31 Jenapharm Gmbh Verwendung von Dienogest in hoher Dosierung
DE10045380A1 (de) 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
US6699820B2 (en) 2001-03-02 2004-03-02 Hartmut Ulrich Bielefeldt Method for making a superconductor with enhanced current carrying capability
IL161105A0 (en) 2001-09-29 2004-08-31 Solvay Pharm Gmbh Estrogen/gestagen combination preparation and application thereof
EP1462106A1 (en) 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
US20050032758A1 (en) 2003-06-25 2005-02-10 Ina Rudolph Hormone replacement therapy and depression
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
MX2007004120A (es) 2004-10-07 2007-06-15 Duramed Pharmaceuticals Inc Metodos de tratamiento hormonal utilizando regimentes de ciclo prolongado de dosis ascendente.
TW200726473A (en) 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
ES2322479T3 (es) 2005-10-13 2009-06-22 Bayer Schering Pharma Aktiengesellschaft Utilizacion de valerato de estradiol en combinacion con dienogest para la terapia por via oral de la hemorragia uterina disfuncional, en union con una contracepcion oral.
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Also Published As

Publication number Publication date
EA016631B1 (ru) 2012-06-29
NZ576336A (en) 2012-03-30
EP1930010A1 (de) 2008-06-11
SV2009003231A (es) 2009-11-09
WO2008046559A1 (de) 2008-04-24
CA2666829A1 (en) 2008-04-24
BRPI0717462A2 (pt) 2013-12-24
AU2007312626A1 (en) 2008-04-24
GT200900090A (es) 2011-11-29
JP2010506867A (ja) 2010-03-04
CA2666829C (en) 2012-02-07
CR10732A (es) 2009-05-25
EA200900491A1 (ru) 2009-10-30
US20080125401A1 (en) 2008-05-29
CO6160297A2 (es) 2010-05-20
KR20090080989A (ko) 2009-07-27
NO20091954L (no) 2009-05-19
US8349820B2 (en) 2013-01-08
IL198200A (en) 2012-10-31
EP2083827A1 (de) 2009-08-05
IL198200A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
MX2009004179A (es) Uso de valerato de estradiol o 17?-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina.
MX347237B (es) Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
MX2008011978A (es) Tratamiento del cancer de seno negativo al triple receptor.
RS20060348A (en) Extended use combination comprising estrogens and progestins
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
RU2009148278A (ru) Применение эстриола в низкой дозе
HUP0402142A2 (hu) Kombinációs ösztrogén-gestagen készítmény és alkalmazása
TW200744672A (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
TW200603787A (en) Topical preparations containing ambroxol
PL382307A1 (pl) Sposób przygotowania farmaceutycznej kompozycji w postaci szybko dyspersyjnej dawki i stała, doustna, szybko dyspersyjna postać dawki
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
NZ630494A (en) Administration of lorcaserin to individuals with renal impairment
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
AR065816A1 (es) Regimen anticonceptivo oral
UA97960C2 (ru) ПРИМЕНЕНИЕ ЭСТРАДИОЛА ВАЛЕРАТА ИЛИ 17β-ЭСТРАДИОЛА В КОМБИНАЦИИ С ДИЕНОГЕСТОМ ДЛЯ ПЕРОРАЛЬНОГО ЛЕЧЕНИЯ ДЛЯ ПОДДЕРЖАНИЯ И/ИЛИ ПОВЫШЕНИЯ ПОЛОВОГО ВЛЕЧЕНИЯ У ОСОБИ ЖЕНСКОГО ПОЛА
CY1111406T1 (el) Χρηση βαλερικης οιστραδιολης ή οιστραδιολης σε συνδυασμο με διενογεστη για την απο του στοματος θεραπεια της αιμορραγιας λογω δυσλειτουργιας της μητρας με τη μορφη απο του στοματος αντισυλληψης
EA200701389A1 (ru) Твёрдая пероральная лекарственная форма для контрацепции
AR049195A1 (es) Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento
MX2007009061A (es) Preparacion farmaceutica para la anticoncepcion oral.
TN2009000263A1 (en) Pharmaceutical preparation for the alleviation of endometriosis
WO2003084521A3 (en) Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
CU20090062A7 (es) Uso de valerato de estradiol o 17beta-estradiol en combinación con dienogest en una terapia oral para mantener y/o incrementar la líbido femenina
DOP2009000079A (es) Uso de valerato de estradiol en combinación con dienogest en una terapia oral para mantener y/o incrementar la líbido femenina
SI1937274T1 (sl) Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo
PE20091020A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa